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Abstract
Background A retrospective study evaluated safety,
symptom resolution, patient satisfaction, and medication
use 1–2 years after transoral incisionless fundoplication
(TIF) in patients with gastroesophageal reﬂux disease
(GERD) and/or laryngopharyngeal reﬂux (LPR) symptoms.
Methods Thirty-four patients with a conﬁrmed diagnosis
of GERD symptoms that were inadequately controlled by
antisecretory medications, and who where either dissatis-
ﬁed with their current therapy or not willing to continue
taking medication, underwent TIF using EsophyX at our
community-based hospital. Follow-up assessments were
completed in 28 patients.
Results Median age of the study group was 57
(range = 23–77) years, BMI was 25.7 (18.3–36.4) kg/m
2,
and 50% were female. All patients had documented chronic
GERDforamedian5(1–20) yearsandrefractorysymptoms
to proton pump inhibitors (PPIs). Hiatal hernia was present
in 75% (21/28) of patients, and 21% (6/28) had erosive
esophagitis(LAgradeAorB).TIFwasperformedfollowing
astandardizedTIF-2protocolandresultedinreducinghiatal
hernia and restoring the natural anatomy of the gastro-
esophageal (GE) junction (Hill grade I). There were no
postoperative complications. At a median 14-months fol-
low-up, 82% (23/28) of patients were off daily PPIs (64%
completely off PPIs), and 68% (19/28) were satisﬁed with
their current health condition compared to 4% before TIF.
Median GERD Health-Related Quality of Life scores were
signiﬁcantly reduced to 4 (0–25) from 26 (0–45) before TIF
(P\0.001). Heartburn was eliminated in 65% (17/26) and
improved by[50% in 86% (24/28) of patients. Regurgita-
tion was eliminated in 80% (16/20) of patients. Atypical
LPR symptoms such as hoarseness, coughing, and throat
clearing were eliminated in 63% (17/27) of patients as
measured by Reﬂux Symptom Index scores.
Conclusion Our results in 28 patients conﬁrm the safety
and effectiveness of TIF, documenting symptomatic
improvement of GERD and LPR symptoms and clinically
signiﬁcant discontinuation of daily PPIs in 82% of patients.
Keywords Heartburn  EsophyX 
Gastroesophageal reﬂux  Hoarseness 
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In a landmark article published 20 years ago, Dr. Bernard
Dallemagne described the ﬁrst laparoscopic Nissen fun-
doplication (LNF) and reported his initial experience with
the ﬁrst 12 patients to undergo this procedure [1]. Since
then, LNF has become the surgical gold standard for the
treatment of gastroesophageal reﬂux disease (GERD) [2].
However, despite its established long-term efﬁcacy and
safety proﬁle, the number of procedures performed in the
United States has sharply declined in the past 10 years [3].
This may be attributed to a number of factors, including
reports of troublesome long-term side effects associated
with LNF, such as gas bloat, dysphagia, and diarrhea [4–7],
and the gradual loss of support from the GI community
which remains the primary source of referrals. Another
cause is surely the perceived efﬁcacy and safety of
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and Other Interventional Techniques proton-pump inhibitors (PPIs), a class of medication that
offers healing of esophagitis and satisfactory symptomatic
relief in the majority of patients with heartburn. However,
several studies have demonstrated that 20–30% of patients
on PPIs are not completely satisﬁed for a variety of reasons
[8, 9]. Furthermore, the magnitude of therapeutic gain from
PPI treatment for regurgitation is relatively modest [10].
There is also a growing awareness in the peer-reviewed
literature and in the public at large about the potential side
effects of life-long PPI acid suppression therapy, including
osteoporosis and increased risks of fractures [11, 12].
The absence of a completely satisfactory modality of
treatment, medical or surgical, has fueled many attempts at
ﬁnding another alternative. A number of endoluminal
devices and approaches to rebuild defective gastroesopha-
geal valves have been developed but have either failed to
deliver acceptable outcomes or have been plagued by
unacceptable rates of morbidity and even mortalities [13].
In contrast, transoral incisionless fundoplication (TIF)
using the EsophyX device (EndoGastric Solutions, Red-
mond, WA) appears to be very promising. The recently
published short term data from the United States [14, 15]
supports the safety and effectiveness of TIF. Bell and
Freeman [14] concluded that this technique should not be
considered experimental, a claim supported by a position
statement from the American Society of General Surgeons
(ASGS) [16]. Additionally, the Society of American Gas-
trointestinal and Endoscopic Surgeons (SAGES) fully
endorses the appropriate use of endoluminal therapy with
proven efﬁcacy in properly selected patients [17]. How-
ever, the lack of long-term outcome data remains a barrier
to adoption of TIF by the wider surgical community as a
reasonable alternative in appropriately selected patients.
Our community-based surgical practice, which special-
izes in antireﬂux surgery, started performing the TIF pro-
cedure in 2008. The purpose of this single-center
retrospective study was to evaluate the longer-term safety
and symptom resolution after the TIF procedure in patients
with chronic GERD and/or laryngopharyngeal reﬂux (LPR)
symptoms. We analyzed 28 patients available for follow-up
with the aim of evaluating symptom elimination, PPI
usage, patient satisfaction, and safety. To our knowledge,
this study is the ﬁrst report of any series from the United
States exceeding one-year follow-up.
Patients and methods
Patients
Thirty-four consecutive patients underwent TIF using the
EsophyX-2 device at our institution between May 2008 and
June 2010. Patients undergoing the same procedure at our
institution after June 2010 were enrolled in a prospective
study (TIF Registry) and were therefore not included. All
thirty-four patients were asked to give their permission to
gather their baseline, TIF, and follow-up data through a
retrospective chart review and were asked to complete a
detailed mail-in questionnaire. Follow-up phone calls were
made and reminder notices were sent when needed. The
data from the 28 patients (82%) who responded were
analyzed. Three patients failed to respond, two others could
not be reached (having moved out of state), and one patient
was terminally ill from ovarian cancer diagnosed in the
interval.
Preoperative assessment
Patients considered for surgery had persistent GERD and/
or LPR symptoms, which were not controlled or only
partially controlled on antisecretory medications, and who
were either dissatisﬁed with their current therapy or
unwilling to continue taking medications indeﬁnitely. All
potential candidates for antireﬂux surgery were subjected
to our routine diagnostic protocol for surgical fundoplica-
tion; a complete history and physical examination, symp-
tom assessment, and other relevant tests. All patients were
required to have undergone the following tests: (1) a recent
EGD to conﬁrm the diagnosis of GERD and rule out the
presence of other esophagogastric pathology; (2) an upper
gastrointestinal series (UGI) to better delineate the GE
junction anatomy and its measurements; and (3) gastro-
esophageal high-resolution manometry (HRM) to rule out
unsuspected esophageal motility abnormalities that may
contraindicate surgery. Twenty-four-hour pH-metry (with
either the Bravo wireless system or a catheter-based com-
bined pH/impedance monitoring system) was administered
whenever the diagnosis of GERD was uncertain, especially
in patients with atypical manifestations. The TIF procedure
was considered appropriate and was offered to the patients
as an alternative to laparoscopic fundoplication when
measurement of the axial height of the hiatal hernia did not
exceed 2 cm.
TIF technique
All procedures were performed using the EsophyX device
and according to the TIF-2 technique described in a white
paper (Bell et al. 2009), which we coauthored. Procedures
were performed in the operating room with the authors
acting as cosurgeons and with the patients under general
orotracheal anesthesia.
The patient is positioned in a left lateral decubitus and in
a slight reverse Trendelenburg position. A preprocedure
gastroscopy is performed to assess the dimensions of the
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123hiatus, assign a Hill grade to the tightness of the GE valve,
and conﬁrm the absence of retained intragastric contents.
The EsophyX-2 device is then gently introduced into the
stomach transorally over the ﬂexible endoscope while
maintaining full endoscopic visualization of the lumen
throughout the insertion phase. The stomach is distended
using air insufﬂation from the gastroscope and CO2
insufﬂation through the working channel of the scope at a
maximum pressure of 12–15 mmHg. A retroﬂex view is
used to observe the tissue mold, elbow, and distal portion
of the chassis crossing the GE junction. The back of the
mold is then aligned to the lesser curvature. The scope is
withdrawn inside the device, allowing for partial closure of
the mold at the elbow, then readvanced into the stomach
and placed in a retroﬂex position. The usual orientation
landmarks are recognized: the lesser curve, the greater
curve, and the anterior and posterior margins of the valve
[18]. Three areas (and six locations) are identiﬁed for pli-
cations: the posterior corner of the valve (the 10 and 11
o’clock locations, to the left of the screen), the anterior
corner of the valve (the 1 and 2 o’clock locations, to the
right of the screen), and the greater curve (the 5 and 7
o’clock locations at the center of the screen). The
deployment of polypropylene H-shaped fastener sets (two
fasteners per set) follows the same steps at each location
(Fig. 1): the helical retractor is placed into the gastric
mucosa within 5 mm of the Z-line, released from the tissue
mold, and used to gently retract the tissue caudad. Suction
is occasionally applied to the tissue invaginator at this
juncture to assist in reducing a small hiatal hernia (if
present) and to insure proper positioning of the level of the
fundoplication in relation to the Z-line. With gentle tension
on the helical retractor, the captured tissue is manipulated
into the tissue mold as the mold is closed while desufﬂating
the stomach. The tissue mold and helical retractor are then
locked into position. Stylets are then slowly advanced
followed by transmural esophagogastric deployment of
fasteners over the stylets, one at a time and under direct
visualization. We thereby use at least 12 (range = 12–16)
plications to create a 240–270 valve by building the
anterior and posterior corners of the reconstructed valve
and achieving 3–4 cm of vertical length by ﬁxing the
gastric fundus to the esophagus at the greater curve. If
deemed necessary by visual inspection, we use up to four
additional fasteners to reinforce or bolster the fundoplica-
tion at the appropriate locations.
Postoperative period
Patients received perioperatively a combination of intra-
venous analgesics, antiemetics, and anticholinergics.
Patients were discharged home the day after surgery, were
given a prescription for oral narcotics, and asked to con-
tinue PPI therapy for 2 weeks. They were allowed to return
to work and drive within 3–5 days. Patients were advised
to follow a postoperative diet during the ﬁrst 6 weeks that
consisted of liquids (2 weeks), soft/pureed foods
(2 weeks), and a soft low residue diet (2 weeks). Patients
were asked to avoid lifting anything heavier than 10–15 lb.
during the ﬁrst 3–5 weeks and not to engage in vigorous
sports and other strenuous activities for the ﬁrst 6 weeks.
Follow-up assessment
All patients were seen back in our ofﬁce approximately
10 days, 6 weeks, and 3 months after surgery and every
6 months thereafter. Patients were asked to contact us upon
the return of any symptom. A request to participate in this
retrospective study was mailed to all patients along with
detailed, disease-speciﬁc questionnaires. Data were col-
lected by reviewing the patients’ charts using paper case
report forms and then entered into Excel spreadsheets. All
data entered was monitored for accuracy and completeness
against the source documents in patient charts. Continuous
variables were summarized as means and standard devia-
tions or medians and ranges.
Age, weight, height, gender, previous medical history,
use of GERD medication, types of GERD symptoms, and
duration of GERD were recorded through review of med-
ical charts. GERD Health-related Quality of Life (GERD-
HRQL), Gastroesophageal Reﬂux Symptom Score
(GERSS), and Reﬂux Symptom Index (RSI) are validated
questionnaires routinely used in clinical practice for
assessing typical and atypical GERD symptoms [13]. All
28 patients completed the GERD-HRQL before TIF
Fig. 1 Modiﬁed schematic drawings of the esophagogastric transoral
incisionless fundoplication (TIF) technique with a depiction of
fastener placement. A similar drawing was presented by Dr. Barnes
and Dr. Hoddinott [15]
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123prospectively at the time of their physical evaluation.
However, all patients were asked to complete preoperative
RSI and GERSS questionnaires by recall. The strength of
the relationship between the retrospective responses and
the prospective GERD-HRQL responses across all domains
of the questionnaires was estimated by the Pearson prod-
uct-moment correlation coefﬁcient. There was a very
strong positive correlation between the regurgitation
questions (r = 0.90, P\0.0001); a strong correlation
between the abdominal distension and coughing questions
(r = 0.77, r = 0.75, P\0.001 in both cases); a moderate
positive correlation between the heartburn questions
(r = 0.68, P\0.001); and a weak, not statistically sig-
niﬁcant correlation between the dysphagia questions
(r = 0.26, P = 0.19). GERD medication use was recorded
as ‘‘none’’ if medication was not taken, ‘‘occasionally’’ if
any dose was taken 1–3 days per week, and ‘‘daily’’ if any
dose was taken 4–7 days per week. Patient satisfaction
with overall health condition was assessed as a part of the
GERD-HRQL questionnaire and was recorded as ‘‘satis-
ﬁed,’’ ‘‘neutral,’’ or ‘‘dissatisﬁed.’’
Effectiveness assessment
The primary clinical effectiveness measure was GERD
symptom elimination at follow-up based on score nor-
malization. Typical symptoms were evaluated using
GERD-HRQL. The GERD-HRQL is a validated disease-
speciﬁc questionnaire measuring ten items (6 related to
heartburn, 2 to dysphagia, 1 to bloating, and 1 to the impact
of medication on daily life) on the VAS scale from 0 (no
symptoms) to 5 (worst symptoms) [19, 20]. The scores
were indicative of rare or eliminated symptoms if none of
the abnormal scores at baseline was [2. The same six
questions as those evaluating heartburn were used to
evaluate regurgitation scores. The GERSS questionnaire
was developed and validated to measure both typical and
atypical symptoms associated with GERD: heartburn,
regurgitation, abdominal distention, dysphagia, and cough
[21, 22]. Each of the ﬁve symptoms was scored as a
product of severity (from 0 = not at all to 3 = severely)
and frequency (0 = never to 4 = daily). The item scores
varied from 0 to 12 and the total scores from 0 to 60.
Patients with controlled reﬂux symptoms by either medical
or surgical therapy are expected to have a total symptom
score of \18 [22]. Atypical symptoms were evaluated
using RSI scores. The RSI is a nine-item questionnaire that
was developed and validated to measure symptoms asso-
ciated with LPR, such as hoarseness, throat clearing, excess
throat mucus, dysphagia, and cough [23]. The scale for
each individual item ranges from 0 (no problem) to 5
(severe problem), with a maximum total score of 45 and a
normality threshold at B13. The follow-up consisted of
symptom evaluation by questionnaires. Scores of B2t o
each question in the GERD-HRQL, GERSS, and RSI
questionnaires were indicative of eliminated symptoms.
We considered a 50% or more reduction in scores at fol-
low-up as a clinically signiﬁcant improvement.
Secondary clinical effectiveness measures were PPI
discontinuation and incidence of any unanticipated serious
and nonserious adverse events, as a measure of safety. The
use of PPIs and other GERD medications such as H2RA
and antacids was recorded. A discontinuation of daily PPI
use, deﬁned as any dose taken B3 days per week, was
considered clinically signiﬁcant.
Patients were stratiﬁed into two groups based on their
primary symptoms and the responses to the GERD-HRQL
questionnaire: a ‘‘typical’’ group that included patients
whose predominant symptoms were heartburn and regur-
gitation, and an ‘‘atypical’’ group, which included patients
whose predominant symptoms were extraesophageal in
nature, representative of LPR symptomatology.
Statistical methods
Statistical analysis was performed using Minitab 15 sta-
tistical software (Minitab Inc., State College, PA). Aggre-
gate data, including patient demographics, baseline
characteristics, efﬁcacy, safety, and patient satisfaction
results, were summarized by descriptive statistics. Mean
and standard deviation were generally reported for con-
tinuous variables. Median and range were reported for data
with skewed distribution. P values for changes at follow-up
compared to those at baseline were calculated using the
Mann–Whitney U test and the paired t test. Fisher’s exact
test was used to compare frequencies. Values with
P\0.05 were considered signiﬁcant. Univariate and
multiple logistic regression analyses were performed to
identify various preoperative predictors of success and
failure. Various factors included in the regression model,
such as BMI (B30 vs.[30), typical and atypical symptom
scores, and presence of esophagitis, were analyzed.
Results
Patient characteristics at baseline
From the 34 patients treated, 28 patients (82%) gave their
permission to access their data and were included in the
study. All patients had documented chronic GERD for a
median of 5 (range = 1–20) years. Median age was
57 years (range = 23–77), BMI ranged from 18.3 to
36.4 kg/m
2, and only one patient was morbidly obese.
Esophagitis was present in 21% of patients, and 14% of
patients had short-segment Barrett’s esophagus, conﬁrmed
Surg Endosc (2012) 26:650–660 653
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Table 1 and show an even distribution between males and
females. The majority of the patients available to follow-up
(82%) were younger than 65 years.
The population of GERD sufferers consisted of patients
with predominant typical GERD symptoms (n = 15, 54%)
and atypical symptoms (n = 13, 46%). Among patients
with predominantly atypical symptoms, 92% (12/13)
complained about constantly clearing their throat, 77% (10/
13) experienced globus sensation, and 69% (9/13) com-
plained about postnasal drip. However, 10/13 (77%)
reported troublesome heartburn and regurgitation as a
secondary complaint. All patients in the atypical subgroup
had abnormal RSI scores (Fig. 2), with inadequate or
partial symptom control despite being on daily (12/13,
92%) or occasional (1/13, 8%) PPI therapy. The majority
of the patients were dissatisﬁed with their current health
condition (12/13, 92%).
The patients stratiﬁed in the typical subgroup suffered
from troublesome heartburn and regurgitation. However,
53% of the typical GERD patients reported severe or
moderate atypical symptoms as a secondary complaint.
Fourteen of 15 (93%) typical GERD patients were dissat-
isﬁed with their current health condition despite daily (13/
15, 87%) or occasional (2/15, 13%) PPI therapy (Fig. 3).
It appears that patients with predominant typical
symptoms experienced marginally better clinical outcomes.
However, this conclusion did not reach statistical
signiﬁcance.
Procedure and safety outcomes
All TIF procedures were completed successfully and
resulted in creating full-thickness esophagogastric fundo-
plications with a median of a 270 (range = 240–300)
wrap around the esophagus, and a length of 3
(range = 2–4) cm above the Z-line. The average length of
time from introduction of the EsophyX device to post-TIF
endoscopy was 55 min. As conﬁrmed endoscopically after
TIF, the small reducible hiatal hernia (B2 cm) present in
75% (21/28) of the patients was completely reduced in all
21 patients. Moderately deteriorated gastroesophageal
junctions (Hill grades II and III) were typically corrected to
Hill grade I after TIF. There were no perioperative com-
plications, and no instances of hospital readmission or
blood transfusion related to use of the EsophyX device. All
28 patients were discharged 1 day after surgery.
Table 1 Baseline characteristics
No. patients 28
Female 14 (50%)
Age (years) 57 (23–77)
\50 12 (43%)
50–65 11 (39%)
[65 5 (18%)
BMI (kg m
-2) 25.7 (18.3–36.4)
C35 kg m
-2 1 (4%)
GERD symptom duration (years) 5 (1–20)
PPI therapy duration (years) 5 (1–11)
Barrett’s esophagus 4 (14%)
Values are medians (range) or counts (%)
BMI body mass index, GERD gastroesophageal reﬂux disease, PPI
proton pump inhibitor
Fig. 2 Percentage of patients
(n = 13) with predominant
troublesome atypical GERD
symptoms as evaluated by RSI
questionnaires before TIF on
daily PPIs and at the median of
17 (range = 3–29) months
follow-up after TIF.P\0.02 in
all cases with signiﬁcant
differences. Associations not
statistically signiﬁcant are
indicated by * (two-tailed
Fisher’s exact test)
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GERD-HRQL
At a median of 14-months (3–29) follow-up, the median
GERD-HRQL scores improved signiﬁcantly to 4 (0–25)
from 26 (0–45) before TIF on PPIs (P\0.001). Typical
GERD symptoms such as heartburn and regurgitation were
eliminated in 65% (17/26) and 80% (16/20), respectively.
GERD-HRQL scores were reduced by more than half in
86% of the patients. Mean changes in the speciﬁc com-
ponents of the GERD-HRQL questionnaire are presented in
Table 2.
GERSS
Median GERSS scores were signiﬁcantly reduced from 24
(9–60) pre-TIF to 3 (0–25) post-TIF and normalized in
61% (17/28) of the patients. The number of patients who
complained about troublesome heartburn (0 vs. 79%),
regurgitation (4 vs. 54%), abdominal distension (18 vs.
39%), dysphagia (0 vs. 29%), and coughing (4 vs. 25 %)
was signiﬁcantly reduced (Fig. 4).
RSI
Median RSI scores were signiﬁcantly reduced from 17
(3–42) pre-TIF on PPIs to 4 (0–22) post-TIF and normal-
ized in 63% (17/23) of the patients. Incidences of trou-
blesome atypical symptoms, evaluated by RSI
questionnaires, were signiﬁcantly reduced across the board
(Fig. 5) and supported atypical symptoms resolution.
Patient satisfaction
Postoperatively, 11% (3/28) of the patients remained dis-
satisﬁed with their current health condition compared to
92% (26/28) before TIF. GERD-speciﬁc scores before and
after TIF are presented in Table 3.
Postoperative PPI use
Twenty three of 28 (82%) patients were off daily PPIs after
TIF compared to 89% with ineffective symptom control
(25/28) on daily PPIs before the TIF procedure. Sixteen of
Fig. 3 Percentage of patients
(n = 15) with predominant
troublesome typical GERD
symptoms as evaluated by
GERD-HRQL questionnaires,
before TIF on daily PPIs (87%)
and at the median of 13
(range = 4–27) months follow-
up after TIF. In all cases with
signiﬁcant differences,
P\0.005, except for **, where
P = 0.04. Association not
statistically signiﬁcant is
indicated by * (two-tailed
Fisher’s exact test)
Table 2 Mean GERD-HRQL scores before TIF on PPIs and after
TIF at 14-months follow-up
Pre-
TIF
Post-
TIF
How bad is your heartburn? 3.3 0.9
Heartburn when lying down? 3.2 0.8
Heartburn when standing up? 2.8 0.5
Heartburn after meals? 3 1
Does heartburn change your diet? 2.9 0.9
Does heartburn wake you from sleep? 2.6 0.4
Do you have difﬁculty swallowing? 2.1 0.3
Do you have pain with swallowing? 1.1 0.1
Do you have bloating and gassy feelings? 2.7 1
If you take GERD medication, does this affect your
daily life?
2.4 0.3
How satisﬁed are you with your present condition?
a 93 11
a Percentage of dissatisﬁed patients
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TIF were completely off PPIs post-TIF. Of the three
patients (11%) who reported taking PPIs occasionally
before TIF, two were completely off PPIs and one
remained on occasional PPI therapy. Post-TIF use of PPIs,
at a median of 14-months follow-up, was reported by 10
patients as either daily (n = 5, 18%) or occasional (n = 5,
18%) and was completely discontinued by the remaining
18 (64%) patients (Fig. 6).
Furthermore, of the 17 patients (65%) who experienced
heartburn elimination, 12 (71%) were completely off PPIs,
4 were taking PPIs occasionally (23%), and 1 was on daily
PPIs (6%). Clinically signiﬁcant discontinuation of daily
PPI use, deﬁned as any dose taken B3 days per week, was
achieved in 16/17 (94%) patients that experienced resolu-
tion of their heartburn.
24-h pH
Ten of 28 patients available for follow-up underwent 24-h
pH testing before TIF on PPIs because they could not
tolerate discontinuation of medical therapy for testing
purposes. Seven of those experienced predominant atypical
symptomatology. Only two patients were willing to
undergo the same test after TIF. In one case, the DeMeester
score was reduced from 29 before TIF to 24.5 after TIF. In
another case, the 24-h pH test off PPIs after TIF was
normal compared to an abnormal test on PPIs before TIF.
Fig. 4 Percentage of patients
(n = 28) with troublesome
typical and atypical GERD
symptoms as evaluated by
GERSS questionnaires before
TIF on PPIs and at the median
of 14 (range = 3–29) months
follow-up after TIF.
*P\0.005; **P = 0.05;
***P = 0.13 (two-tailed
Fisher’s exact test)
Fig. 5 Percentage of patients
(n = 28) with troublesome
atypical GERD symptoms
before TIF on PPIs and at the
median of 14 (range = 3–29)
months follow-up after TIF.
Symptom scores were obtained
using RSI questionnaires. In all
cases with signiﬁcant
differences, P B 0.02, except
for **, where P = 0.055
(approaching signiﬁcance).
Association not statistically
signiﬁcant is indicated by *
(two-tailed Fisher’s exact test)
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One patient underwent TIF to LNF conversion 6 months
after failed TIF. During the procedure, we found that the
fasteners had become dislodged from the fundus of the
stomach. The patient’s authentication of habitual overeat-
ing led us to conclude that the post-TIF dietary recom-
mendations were not followed and the reconstructed valve
was disrupted. This revision was easy to perform and the
patient had an uneventful recovery.
Discussion
This study is the culmination of our efforts to critically
evaluate the clinical outcomes of the ﬁrst patients on whom
we performed TIF procedures. We became interested in
adding TIF to our community-based antireﬂux surgery
practice shortly after the EsophyX device gained FDA
clearance, and following publication of the ﬁrst multicenter
data series by Cadiere et al. [24, 25]. His data had been
generated using an earlier version of the TIF technique
(commonly referred to as TIF-1), which relied primarily on
gastrogastric plications below the Z-Line. The data dem-
onstrated encouraging levels of clinical reﬂux control and a
complete absence of any post-fundoplication side effects,
and conﬁrmed the exceptional safety proﬁle of the TIF-1,
which had been previously established by the phase I sin-
gle-center trials.
Most patients enrolled in our study were referred to us
by gastroenterologists, ENT specialists, and pulmonolo-
gists. Generally, patients sought alternative treatments for
GERD either because of symptoms refractory to medical
therapy or unwillingness to accept the risks associated with
lifelong use of PPIs. During ofﬁce consultations, LNF was
discussed and presented as a well-established and effective
surgical option in treating both acid and nonacid reﬂux
[26–29]. A signiﬁcant percentage of patients had large
hiatal hernias in excess of 2 cm in axial height, and sub-
sequently underwent LNF. However, a majority of patients
with hiatal hernias smaller than 2 cm and who were given a
Table 3 GERD health-related quality of life (GERD-HRQL), reﬂux
symptom index (RSI), gastroesophageal reﬂux symptom score
(GERSS) scores before esophagogastric transoral incisionless fun-
doplication (TIF) surgery while on PPIs and at a median 14 (3–29)
months after surgery (n = 28)
Pre-TIF Post-TIF p value
GERD-HRQL scores
Median (range) 26 (0–45) 4 (0–25) \0.001
Mean (SEM) 26.4 (5.0) 6.0 (1.1) \0.001
Abnormal [n (%)]
a 26/28 (93%) 7/28 (25%) \0.001
Improved by 50%
[n (%)]
b
24/28 (86%)
Normalized [n (%)]
c 17/26 (65%)
RSI scores
Median (range) 17 (3–42) 4 (0–22) \0.001
Mean (SEM) 19.2 (3.6) 6.1 (1.1) \0.001
Abnormal [n (%)]
a 27/28 (96%) 10/28 (36%) \0.001
Improved by 50%
[n (%)]
b
22/28 (79%)
Normalized [n (%)]
d 17/27 (63%)
GERSS scores
Median (range) 24 (9–60) 3 (0–25) \0.001
Mean (SEM) 26.8 (5.1) 4.6 (0.9) \0.001
Abnormal [n (%)]
a 28/28 (100%) 11/28 (39%) \0.001
Improved by 50%
[n (%)]
b
27/28 (96%)
Normalized [n (%)]
d 17/28 (61%)
Regurgitation score
Median (range) 16 (0–30) 0 (0–15) \0.001
Mean (SEM) 14.9 (2.8) 2.8 (0.5) \0.001
Abnormal [n (%)]
a 20/28 (71%) 4/28 (14%) \0.001
Improved by 50%
[n (%)]
b
21/28 (75%)
Normalized [n (%)]
d 16/20 (80%)
Satisfaction index
e
Satisﬁed [n (%)] 1/28 (4%) 19/28 (68%) \0.001
Neutral [n (%)] 1/28 (4%) 6/28 (21%) \0.001
Dissatisﬁed [n (%)] 26/28 (92%) 3/28 (11%) \0.001
P\0.05 indicates signiﬁcant difference
a Abnormal if any individual score[2
b Compared to baseline on PPIs
c Normalized RSI score deﬁned by a total score of B13 with each
question evaluated as eliminated or rare (score B2)
d Normalized if none of the abnormal scores at baseline is [2a t
follow-up
e Satisfaction index determined using GERD-HRQL indicates patient
satisfaction with current health condition
Fig. 6 Bars represent number of patients on daily, occasionally, and
completely off PPI therapy before and after TIF. Post-TIF, only 18%
(5/28) of patients remained on daily PPIs at 14-months follow-up
compared to 89% (25/28) before TIF; P\0.001
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123choice between the two procedures ultimately elected to
undergo a TIF because of the attractiveness of an inci-
sionless procedure, its safety proﬁle, and the expectation of
not having to suffer from any of the known post-fundo-
plication side effects such as dysphagia and gas bloat [7].
The available clinical effectiveness data from published
TIF studies was shared with our patients for full disclosure.
All our patients underwent a TIF-2 procedure [30], a
modiﬁcation of the TIF-1 which entails placement of gas-
troesophageal plications to create a partial anterior esoph-
agogastric fundoplication above the Z-line. By creating a
more robust and more physiologic valve at the gastro-
esophageal junction, this technique met the expectation of
improved reﬂux control in comparison to TIF-1 in short-
term follow-up reports [14, 15].
Regarding clinical effectiveness, a remarkable improve-
ment in both typical and atypical symptoms was noted in
our postoperative patient population and reached statistical
signiﬁcance with all three scoring methodologies (GERD-
HRQL, RSI, and GERSS). Clinical improvement by a
score reduction of more than 50% occurred in 79–96%,
while complete normalization was achieved in 61–65%
of the cases. The pattern of antisecretory drug use was
also dramatically affected in patients undergoing the TIF
procedure, with fewer than 20% on daily PPI therapy fol-
lowing surgery. Patient satisfaction was high. Our data
therefore suggest that the same level of clinical effective-
ness is reproducible and durable with longer follow-up
periods. In addition, we are greatly encouraged by the
absence of any perioperative complications or debilitating
side effects such as gas bloat or new onset of dysphagia in
our series. This conﬁrms the experience of others [14, 15]
and could represent a favorable shift in the risk-beneﬁt
ratio as compared to the more traditional antireﬂux surgical
options, and is one of the most attractive and promising
aspects of the TIF procedure in our view.
Reports suggest that the normalization of esophageal
acid exposure and a number of reﬂux episodes after TIF
could be achieved in up to 61 and 89% of patients,
respectively [14]. We elected to offer the TIF procedure to
four patients with short-segment Barrett’s esophagus
(B2 cm) and non-neoplastic changes to alleviate their
severe GERD symptoms, improve their quality of life, and
ideally stop the advancement of Barrett’s. All four treated
patients experienced a remarkable improvement in their
symptom scores and medication use after TIF. These
patients were placed on a standard Barrett’s surveillance
protocol with screening EGDs by their gastroenterologists.
Our attempt to determine the preoperative predictors of
success and failure did not reach statistical signiﬁcance. If
we consider the responders only those patients who were
completely off PPIs at a median of 14-months follow-up,
the patients with severe heartburn (responses 4 or 5 on the
ﬁrst three GERD-HRQL questions) appeared to be at a
higher risk of using PPIs at least occasionally after the TIF
procedure. However, this conclusion was statistically
insigniﬁcant. Interestingly, a majority of patients (60%)
who were on occasional or daily PPI therapy after TIF had
their total GERD-HRQL and RSI scores normalized.
Moreover, 90 and 70% had experienced C50% improve-
ment in total HRQL and RSI scores, respectively. Although
these patients remained on medical therapy, their GERD
symptoms were well controlled compared to uncontrolled
severe symptoms before TIF. Therefore, we were not sur-
prised with the patients’ refusal to undergo additional
testing and an alternative procedure.
Examining the time of symptom reoccurrence after TIF,
we observed that nine of ten patients started occasional or
daily PPI therapy less than 4 months after the procedure.
One patient requested medication 8 months after TIF
because of heartburn symptoms and postprandial epigastric
pain. In this case, an abdominal ultrasound conﬁrmed our
suspicion of cholelithiasis. An endoscopic evaluation of the
previously constructed reﬂux barrier revealed a completely
intact, 270 omega-shaped valve in place, without the
presence of a hiatal hernia. In all ten cases, the pattern of
medication use after initial prescription remained the same
over time. Based on these facts, we speculate that the
patients off PPIs at 4 months after TIF are likely to remain
off PPIs for a longer term.
We owe our strong results to thorough preoperative
work-ups and adherence to stringent inclusion criteria.
Still, we elected to include patients with dominant or pure
LPR symptomatology and proven reﬂux, even though it has
been shown conclusively that this patient population
responds less often to conventional surgical treatment [26,
31–33]. However, the comparative effectiveness of surgery
compared to medical treatment impacted our decision,
supported by our belief in the safety proﬁle of the TIF
procedure.
Three patients dissatisﬁed with their current health
condition were reevaluated. One patient had a signiﬁcant
history of metastatic testicular cancer considered in
remission. The patient’s preoperative symptoms were
mostly laryngopharyngeal, initially improved after TIF,
and both EGD and UGI revealed complete reduction of his
hiatal hernia after TIF. The second patient admitted lifting
heavy luggage 3 weeks after the procedure and as a result
experiencing sudden and severe epigastric discomfort for
24 h. The third patient became car sick on his way home
(2 h away) the day after surgery and experienced violent
retching and vomiting. We suspect that in these latter two
cases, the freshly constructed valve was disrupted by vio-
lent shearing forces. This emphasizes the importance of
refraining from strenuous physical activities and avoidance
of vomiting at all costs in the early postoperative period.
658 Surg Endosc (2012) 26:650–660
123Five patients who remained on daily PPIs after TIF expe-
rienced reduction in their mean GERD-HRQL, GERSS,
RSI, and regurgitation scores by 73, 71, 67, and 70%,
respectively. This may suggest that TIF achieved a positive
impact and relative success in improving the quality of life
of these patients despite an unchanged pattern of PPI use.
We strongly believe that the management of chronic
refractory GERD requires an interdisciplinary approach. In
our community setting, patients seek help when their
GERD symptoms become intolerable despite high-dose
PPI therapy. Their main therapeutic goals are to alleviate
symptoms and improve quality of life. In three cases after
TIF, we referred the patients stratiﬁed to the atypical group
to a speech therapist and ENT specialist because we felt
that their symptoms were no longer related to GERD.
Although our results support the clinical effectiveness
and safety of the TIF procedure, we realize the limitations
of this retrospective single-center study, which concerns a
small number of patients and which lacks follow-up com-
parative pH/impedance monitoring data. We believe,
however, that it is valuable because it includes all patients
treated over a 2-year period, without selection bias, with a
relatively long-term median follow-up of 14 months, and
with a high positive proportion of responders (more than
80%).
In addition, it should be understood that this study
represents our initial learning curve. The EsophyX device
itself has seen improvements since we started using it, and
the technique underwent modiﬁcations. As a consequence
of this critical look at our early experience and its results,
we feel justiﬁed in continuing to offer the TIF as an option
to well-selected and appropriate surgical candidates. We
are planning to report 2- and 3-year follow-up data that will
include endoscopic evaluation of the same patient popu-
lation at a later time. To address some of the limitations of
this study, we are currently enrolling new patients in a
prospective multicenter TIF Registry.
Conclusion
Our results conﬁrm the safety proﬁle of TIF and demon-
strate its effectiveness in eliminating typical and atypical
GERD symptoms at a median of 14-months follow-up. Our
study supports the adoption of TIF as an alternative treat-
ment option for selected patients with inadequate symptom
control on PPI therapy.
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